Soleno Therapeutics (SLNO) Cash & Current Investments (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Cash & Current Investments data on file, last reported at $255.6 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 11.85% year-over-year to $255.6 million in Q1 2026; TTM through Mar 2026 was $255.6 million, a 11.85% decrease from a year earlier, with the FY2025 full-year figure at $305.5 million, up 4.82% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $255.6 million, down from $305.5 million in the prior quarter.
• Over the last five years, Cash & Current Investments for SLNO reached as high as $499.0 million in Q3 2025 and fell as low as $7.9 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $172.8 million across 5 years, with a median of $169.7 million in 2023.
• Across the five-year window, Cash & Current Investments tumbled 72.73% in 2023 and jumped 1793.67% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $14.6 million in 2022, then surged by 1062.04% to $169.7 million in 2023, then surged by 71.76% to $291.4 million in 2024, then advanced by 4.82% to $305.5 million in 2025, then declined by 16.34% to $255.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $255.6 million in Q1 2026, $305.5 million in Q4 2025, and $499.0 million in Q3 2025.